BrightPath Biotherapeutics Co., Ltd. (4594.T)
JPY 40.0
(-2.44%)
JPY 40.0
(-2.44%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 1.23 Billion JPY | -27.69% |
| 2022 | 1.7 Billion JPY | -38.6% |
| 2021 | 2.77 Billion JPY | -26.09% |
| 2020 | 3.74 Billion JPY | 7.91% |
| 2019 | 3.47 Billion JPY | -34.5% |
| 2018 | 5.3 Billion JPY | -26.69% |
| 2017 | 7.23 Billion JPY | 33.79% |
| 2016 | 5.4 Billion JPY | 87.97% |
| 2015 | 2.87 Billion JPY | 134.41% |
| 2014 | 1.22 Billion JPY | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 822.76 Million JPY | -33.12% |
| 2023 Q3 | 1.42 Billion JPY | 22.76% |
| 2023 FY | 1.23 Billion JPY | -27.69% |
| 2023 Q4 | 1.23 Billion JPY | -13.88% |
| 2023 Q1 | 1.38 Billion JPY | -18.46% |
| 2023 Q2 | 1.16 Billion JPY | -16.13% |
| 2022 Q4 | 1.7 Billion JPY | -13.85% |
| 2022 Q3 | 1.97 Billion JPY | -6.73% |
| 2022 Q2 | 2.11 Billion JPY | -7.21% |
| 2022 Q1 | 2.28 Billion JPY | -17.66% |
| 2022 FY | 1.7 Billion JPY | -38.6% |
| 2021 Q1 | 3.31 Billion JPY | -11.47% |
| 2021 Q2 | 3.2 Billion JPY | -3.52% |
| 2021 Q3 | 2.86 Billion JPY | -10.69% |
| 2021 FY | 2.77 Billion JPY | -26.09% |
| 2021 Q4 | 2.77 Billion JPY | -3.11% |
| 2020 Q2 | 4.31 Billion JPY | 8.64% |
| 2020 Q3 | 3.97 Billion JPY | -7.94% |
| 2020 Q4 | 3.74 Billion JPY | -5.63% |
| 2020 FY | 3.74 Billion JPY | 7.91% |
| 2020 Q1 | 3.97 Billion JPY | 14.32% |
| 2019 Q3 | 3.99 Billion JPY | -9.64% |
| 2019 FY | 3.47 Billion JPY | -34.5% |
| 2019 Q1 | 4.82 Billion JPY | -8.96% |
| 2019 Q4 | 3.47 Billion JPY | -13.1% |
| 2019 Q2 | 4.42 Billion JPY | -8.36% |
| 2018 Q2 | 6.16 Billion JPY | -6.55% |
| 2018 Q1 | 6.59 Billion JPY | -8.85% |
| 2018 Q3 | 5.69 Billion JPY | -7.67% |
| 2018 Q4 | 5.3 Billion JPY | -6.79% |
| 2018 FY | 5.3 Billion JPY | -26.69% |
| 2017 Q4 | 7.23 Billion JPY | 61.83% |
| 2017 FY | 7.23 Billion JPY | 33.79% |
| 2017 Q1 | 5.09 Billion JPY | -5.71% |
| 2017 Q2 | 4.76 Billion JPY | -6.61% |
| 2017 Q3 | 4.47 Billion JPY | -6.11% |
| 2016 Q2 | 4.06 Billion JPY | 3.67% |
| 2016 Q1 | 3.92 Billion JPY | 36.34% |
| 2016 FY | 5.4 Billion JPY | 87.97% |
| 2016 Q4 | 5.4 Billion JPY | 20.15% |
| 2016 Q3 | 4.5 Billion JPY | 10.7% |
| 2015 Q4 | 2.87 Billion JPY | -8.98% |
| 2015 Q3 | 3.16 Billion JPY | 394.55% |
| 2015 Q2 | 639.18 Million JPY | 0.0% |
| 2015 FY | 2.87 Billion JPY | 134.41% |
| 2014 FY | 1.22 Billion JPY | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 6.58 Billion JPY | 81.33% |
| PRISM BioLab Co.,LTD | 1.21 Billion JPY | -1.554% |
| GNI Group Ltd. | 62.39 Billion JPY | 98.028% |
| Linical Co., Ltd. | 18.53 Billion JPY | 93.364% |
| Trans Genic Inc. | 9.81 Billion JPY | 87.46% |
| MEDINET Co., Ltd. | 5.63 Billion JPY | 78.164% |
| Soiken Holdings Inc. | 6.94 Billion JPY | 82.289% |
| Cytori Cell Research Institute, Inc. | 5.81 Billion JPY | 78.848% |
| AnGes, Inc. | 28.89 Billion JPY | 95.742% |
| OncoTherapy Science, Inc. | 867.27 Million JPY | -41.853% |
| Nxera Pharma Co., Ltd. | 157.19 Billion JPY | 99.217% |
| Immuno-Biological Laboratories Co., Ltd. | 1.61 Billion JPY | 23.992% |
| NanoCarrier Co., Ltd. | 5.07 Billion JPY | 75.741% |
| Carna Biosciences, Inc. | 4.34 Billion JPY | 71.718% |
| CanBas Co., Ltd. | 2.43 Billion JPY | 49.432% |
| D. Western Therapeutics Institute, Inc. | 2.37 Billion JPY | 48.164% |
| RaQualia Pharma Inc. | 6.93 Billion JPY | 82.248% |
| Chiome Bioscience Inc. | 1.75 Billion JPY | 29.758% |
| Kidswell Bio Corporation | 5.08 Billion JPY | 75.809% |
| PeptiDream Inc. | 67.12 Billion JPY | 98.167% |
| Oncolys BioPharma Inc. | 2.04 Billion JPY | 39.711% |
| Ribomic Inc. | 3.54 Billion JPY | 65.318% |
| SanBio Company Limited | 5.04 Billion JPY | 75.625% |
| Healios K.K. | 15.15 Billion JPY | 91.882% |
| Kubota Pharmaceutical Holdings Co., Ltd. | 3.01 Billion JPY | 59.209% |
| Delta-Fly Pharma, Inc. | 1.47 Billion JPY | 16.545% |
| StemRIM | 9.08 Billion JPY | 86.451% |
| CellSource Co., Ltd. | 6.87 Billion JPY | 82.118% |
| FunPep Company Limited | 2.49 Billion JPY | 50.615% |
| Kringle Pharma, Inc. | 2.61 Billion JPY | 53.02% |
| Stella Pharma Corporation | 3.82 Billion JPY | 67.8% |
| TMS Co., Ltd. | 3.55 Billion JPY | 65.391% |
| Noile-Immune Biotech Inc. | 5.77 Billion JPY | 78.711% |
| Cuorips Inc. | 6.18 Billion JPY | 80.108% |
| K Pharma,Inc. | 3.31 Billion JPY | 62.876% |
| Takara Bio Inc. | 123.2 Billion JPY | 99.001% |
| ReproCELL Incorporated | 9.05 Billion JPY | 86.41% |
| PhoenixBio Co., Ltd. | 2.71 Billion JPY | 54.692% |
| StemCell Institute Inc. | 6.54 Billion JPY | 81.198% |
| Japan Tissue Engineering Co., Ltd. | 6.98 Billion JPY | 82.397% |
| CellSeed Inc. | 2.46 Billion JPY | 50.107% |